Form 4: Assembly Biosciences Director Receives Stock Option Grant
Statement of Changes in Beneficial Ownership
Director Gina Consylman was granted 8,000 stock options in Assembly Biosciences, Inc. as part of a standard equity compensation arrangement.
Summary
- Director Gina Consylman received a grant of 8,000 stock options for Assembly Biosciences, Inc. (ASMB) common stock.
- The options have an exercise price of $24.11 per share.
- The grant date for the transaction was June 4, 2026.
- The options are scheduled to vest on the earlier of June 4, 2027, or the date of the 2027 annual meeting of stockholders.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.
Positives
- Alignment of director interests with long-term shareholder value through equity-based compensation.
Negatives
- The grant results in potential future dilution for existing shareholders upon exercise.
Risks
- Market volatility affecting the value of the underlying common stock relative to the $24.11 exercise price.
Future Outlook
The options vest in one year, contingent upon continuous service, aligning the director's tenure with the company's performance through June 2027.
Industry Context
StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice in the biotechnology sector to ensure board members maintain a vested interest in company performance.
Comparison to Industry Standards
- The grant size and vesting schedule are consistent with typical director compensation packages for small-cap biotechnology firms.
- The use of a one-year cliff vesting period is a standard retention mechanism for board members.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Director Compensation | Grant of 8,000 stock options to Director Gina Consylman. | 06/04/2026 | Standard alignment of director incentives with shareholder interests. |
Stakeholder Impact
- Shareholders: Minor dilution impact upon future exercise of options.
- Director: Increased equity stake in the company.
Next Steps
- Vesting of options on June 4, 2027, or the 2027 annual meeting date.
Key Dates
| Date | Description |
|---|---|
| 06/04/2026 | Date of the stock option grant transaction. |
| 06/05/2026 | Date the Form 4 was signed and filed. |
| 06/04/2027 | Vesting date for the granted stock options. |
| 06/04/2036 | Expiration date of the granted stock options. |
Keywords
Assembly Biosciences, ASMB, Form 4, Insider Trading, Stock Options, Director Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.